Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALLR3 (Children's Cancer and Leukaemia Group)
- Development stage
- Unknown
- Lead developer
- Children's Cancer and Leukaemia Group
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Oral, Intrathecal
01
Overview
ALLR3 is a multi-agent chemotherapy regimen established as a standard of care for pediatric patients with relapsed B-cell precursor acute lymphoblastic leukemia (BCP ALL). The regimen was originally defined in the UKALLR3 clinical trial and typically includes an induction phase consisting of mitoxantrone, vincristine, dexamethasone, and asparaginase, supplemented by intrathecal methotrexate for central nervous system prophylaxis. It is frequently utilized as the control arm in contemporary clinical trials evaluating novel agents, such as inotuzumab ozogamicin, for high-risk or very high-risk relapsed ALL.
- Other names
- UKALLR3 regimenUKALLR-3 regimenUKALLR 3 regimenALL-R3 protocolALL-R-3 protocolALL-R 3 protocol
02
Targets
TUBB (Tubulin (alpha and beta subunits))GR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on ALLR3 (Children's Cancer and Leukaemia Group).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALLR3 (Children's Cancer and Leukaemia Group).